Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Pipeline Review, H1 2018

  • ID: 4464909
  • Report
  • 113 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Amgen Inc
  • Amorepacific Corp
  • BCN Peptides SA
  • DoNatur GmbH
  • Flex Pharma Inc
  • Grunenthal GmbH
  • MORE
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Pipeline Review, H1 2018

Summary:

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) pipeline Target constitutes close to 37 molecules. Out of which approximately 29 molecules are developed by companies and remaining by the universities/institutes.

The latest report Transient Receptor Potential Cation Channel Subfamily V Member 1 - Pipeline Review, H1 2018, outlays comprehensive information on the Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - The transient receptor potential cation channel subfamily V member 1 (TrpV1) is a protein encoded by the TRPV1 gene. It belongs to a sub-family of the transient receptor potential protein group. It mediates proton influx and may be involved in intracellular acidosis in nociceptive neurons. It is involved in mediation of inflammatory pain and hyperalgesia. It sensitized by a phosphatidylinositol second messenger system activated by receptor tyrosine kinases, which involves PKC isozymes and PCL. It is activated by endogenous compounds, including 12-hydroperoxytetraenoic acid and bradykinin.

It acts as ionotropic endocannabinoid receptor with central neuromodulatory effects. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 9, 6, 10 and 1 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 6 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Musculoskeletal Disorders, Cardiovascular, Metabolic Disorders, Dermatology, Gastrointestinal, Genito Urinary System And Sex Hormones, Ophthalmology, Immunology, Oncology and Respiratory which include indications Osteoarthritis Pain, Cancer Pain, Inflammatory Pain, Muscle Spasm, Muscle Spasticity, Neuro Muscular Disorders, Neuropathic Pain, Pain, Postherpetic Neuralgia, Acute Pain, Chronic Pain, Congestive Heart Failure (Heart Failure), Diabetic Peripheral Neuropathy, Pruritus, Abdominal Pain, Alzheimer's Disease, Atherosclerosis, Atopic Dermatitis, Autoimmune Hepatitis, Breast Cancer, Cardiomegaly, Cluster Headache Syndrome, Cough, Crohn's Disease (Regional Enteritis), Demyelinating Diseases, Inflammation, Insomnia, Keratoconjunctivitis sicca (Dry Eye), Morton Metatarsalgia, Ocular Hypertension, Ocular Pain, Open-Angle Glaucoma, Overactive Bladder, Post-Operative Pain, Prostate Cancer, Radiculopathy, Renal Failure, Rosacea, Seborrhea, Squamous Cell Carcinoma, Type 2 Diabetes and Visceral Pain.

Furthermore, this report also reviews key players involved in Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1)
  • The report reviews Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amgen Inc
  • Amorepacific Corp
  • BCN Peptides SA
  • DoNatur GmbH
  • Flex Pharma Inc
  • Grunenthal GmbH
  • MORE
Introduction

The Publisher's Report Coverage

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Overview

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Companies Involved in Therapeutics Development

Amgen Inc

Amorepacific Corp

BCN Peptides SA

Centrexion Therapeutics Corp

Daewoong Pharmaceutical Co Ltd

DoNatur GmbH

Flex Pharma Inc

Grunenthal GmbH

Kyowa Hakko Kirin Co Ltd

Medifron DBT Co Ltd

Neurim Pharmaceuticals Ltd

Pila Pharma AB

Sylentis SAU

Toray Industries Inc

Vitality Biopharma Inc

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Drug Profiles

AMG-986 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CA-008 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CA-011 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CA-016 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cannabidiol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

capsaicin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

capsaicin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CMX-020 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DD-04107 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DWP-05195 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FLX-787 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FLX-788 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FLX-797 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FLX-798 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

K-685 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MCS-18 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MDR-16523 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MDR-652 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit TRPV1 for Inflammatory Pain and Cancer Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MTX-071 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NEO-6860 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NeuP-12 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PAC-14028 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Target TRPV1 for Pain and Itch - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

piromelatine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

QX-314 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

resiniferatoxin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Block TRPV1 for Congestive Heart Failure and Cardiomegaly - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Block TRPV1 for Overactive Bladder - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Block TRPV1 for Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Block TRPV1 for Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate TRPV1 Channel for Pain and Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate TRPV1 for Demyelinating Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Block TRPA1 and TRPV1 for Central Nervous System - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Block TRPV1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tivanisiran - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XEND-0501 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

zucapsaicin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Dormant Products

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Discontinued Products

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Product Development Milestones

Featured News & Press Releases

Jan 30, 2018: Revive Therapeutics Advances Research Program of Cannabinoid-Based Therapies Targeting Liver Diseases

Jan 16, 2018: Centrexion Therapeutics Announces Fast Track Designation Granted by FDA to CNTX-4975 for Treatment of Knee Osteoarthritis Pain

Jan 02, 2018: Centrexion Therapeutics Launching Phase 3 Program for CNTX-4975 in Knee Osteoarthritis Pain in 2018

Dec 07, 2017: Concentric Analgesics Receives FDA Fast Track Designation for CA-008 for Post-Surgical Pain

Nov 28, 2017: Enrollment Completed in Flex Pharmas Phase II Exploratory Spasticity Study in MS

Nov 06, 2017: Flex Pharma Reports Positive Topline Data from Exploratory Phase 2 Trial of FLX-787 in ALS

Nov 02, 2017: Concentric Analgesics Launches CA-008 Clinical Development Program in Post-Surgical Pain

Oct 30, 2017: Centrexion Therapeutics Announces Multiple Data Presentations on CNTX-4975 at the American College of Rheumatology Annual Meeting

Oct 30, 2017: NEO6860 Phase II Data to be Presented at the American College of Rheumatology’s Annual Meeting

Oct 19, 2017: The World Health Organization Selects Tivanisiran as the International Nonproprietary Name for SYL

Oct 16, 2017: Flex Pharma Initiates CMT Phase 2 Trial with FLX-787 in US

Sep 27, 2017: Revive Therapeutics Applies to FDA for Orphan Drug Designation for Treatment of Autoimmune Hepatitis

Sep 26, 2017: Centrexion Therapeutics to Present Phase 2b data of Osteoarthritis Drug Candidate CNTX-4975 at the 11th Annual Pain and Migraine Therapeutics Summit

Aug 29, 2017: Centrexion Therapeutics to Present 6-Month Efficacy Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Knee Osteoarthritis at PAINWeek

Aug 01, 2017: Flex Pharma Initiates ALS Phase 2 Trial with FLX-787 in US

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1)

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Amgen Inc, H1 2018

Pipeline by Amorepacific Corp, H1 2018

Pipeline by BCN Peptides SA, H1 2018

Pipeline by Centrexion Therapeutics Corp, H1 2018

Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2018

Pipeline by DoNatur GmbH, H1 2018

Pipeline by Flex Pharma Inc, H1 2018

Pipeline by Grunenthal GmbH, H1 2018

Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2018

Pipeline by Medifron DBT Co Ltd, H1 2018

Pipeline by Neurim Pharmaceuticals Ltd, H1 2018

Pipeline by Pila Pharma AB, H1 2018

Pipeline by Sylentis SAU, H1 2018

Pipeline by Toray Industries Inc, H1 2018

Pipeline by Vitality Biopharma Inc, H1 2018

Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd..1), H1 2018

Dormant Products, H1 2018 (Contd..2), H1 2018

Dormant Products, H1 2018 (Contd..3), H1 2018

Dormant Products, H1 2018 (Contd..4), H1 2018

Discontinued Products, H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Top 10 Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Amgen Inc
  • Amorepacific Corp
  • BCN Peptides SA
  • Centrexion Therapeutics Corp
  • Daewoong Pharmaceutical Co Ltd
  • DoNatur GmbH
  • Flex Pharma Inc
  • Grunenthal GmbH
  • Kyowa Hakko Kirin Co Ltd
  • Medifron DBT Co Ltd
  • Neurim Pharmaceuticals Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll